Partnership will expand access to Lutetium-177 for radiopharmaceutical developers
ITM Isotope Technologies Munich SE has entered into a supply agreement with radiopharmaceutical contract development and manufacturing organization AtomVie Global Radiopharma to provide non-carrier-added lutetium-177 (Lu-177) for the company's manufacturing operations.
Lu-177 is a therapeutic radioisotope commonly paired with targeting molecules that deliver it to specific tumor sites. Once localized, the isotope emits beta radiation to damage cancer cells while limiting exposure to surrounding tissue. The non-carrier-added form supplied by ITM is a highly pure version of the isotope used in radiopharmaceutical development and manufacturing.
The new agreement is intended to strengthen AtomVie's radioisotope supply chain and expand access to Lu-177 for radiopharmaceutical developers. AtomVie will use the material to support its contract manufacturing activities for pharmaceutical and biotechnology companies developing radiopharmaceutical products. The agreement is expected to provide AtomVie and its partners with a more dependable source of the isotope.
“AtomVie serves multiple, diverse radiopharmaceutical companies across the industry, all of which rely on dependable supply of high-quality radioisotopes,” Bruno Paquin, CEO of AtomVie, said in an announcement on the partnership. “By strengthening this relationship with ITM, a global leader in isotope production, we and our current and future partners have dependable access to [Lu-177] to support therapeutic and diagnostic development programs.”
ITM holds a U.S. Food and Drug Administration Drug Master File for Lu-177 and has European Union marketing authorization for the isotope under the brand name EndolucinBeta. The company is commissioning a new 72,300-square-foot manufacturing facility in Hamilton, Ontario, which is expected to expand its capabilities.
The partnership comes as reliable access to medical radioisotopes has been under strain due to numerous supply chain disruptions in recent years. Neither company disclosed financial terms or specific supply volumes under the agreement.
